Azilsartan medoxomil (Standard)

Azilsartan medoxomil (Standard) is the analytical standard of Azilsartan medoxomil. This product is intended for research and analytical applications. Azilsartan medoxomil (TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension[1][2][3][4].

Product Specifications

CAS Number

[863031-21-4]

Product Name Alternative

TAK-491 (Standard)

UNSPSC

12352005

Target

Angiotensin Receptor; Reference Standards

Type

Reference Standards

Related Pathways

GPCR/G Protein; Others

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/azilsartan-medoxomil-standard.html

Smiles

O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NC(ON5)=O)C=C3)=CC=C1)OCC6=C(C)OC(O6)=O

Molecular Formula

C30H24N4O8

Molecular Weight

568.53

References & Citations

[1]Kajiya T, Ho C, Wang J, Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011 Dec;29 (12) :2476-83.|[2]Kusumoto K, Igata H, Ojima M, Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.|[3]Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012 Sep 1;32 (9) :621-39.|[4]Pierini D, Anderson KV. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. Ann Pharmacother. 2013 May;47 (5) :694-703.|[5]French CJ, et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol. 2011 Aug;58 (2) :143-8. |[6]Ye Y, et al. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr;24 (2) :107-20.